Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BI, Lilly To Study Jardiance As Heart Failure Therapy

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim and Eli Lilly will launch two outcomes trials within the next 12 months investigating their jointly developed diabetes medicine Jardiance (empagliflozin) as a treatment for people with chronic heart failure – enrolling patients both with and without type 2 diabetes.

You may also be interested in...



Entresto Facing Pressure From Diabetes Drugs

With diabetes therapeutics adding cardiovascular risk reduction claims, Novartis's heart failure drug Entresto could face pressure from new fronts – just as sales start to take off.

Lilly Diabetes Extends Feelers Into Other Diseases

Eli Lilly leads the way in diabetes and is using its current portfolio to find advantageous opportunities in related therapeutic areas.

Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.

Topics

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel